Search For "lupin ltd"
Lupin sales grow 22 pc to Rs 4,237 cr in Q1 FY22
Updated : 4 years, 7 months ago IST
Mumbai (Maharashtra) [India], August 11 (ANI): Pharma major Lupin Ltd has reported consolidated sales of Rs 4,237 crore in the first quarter of current financial year (Q1 FY22), up 13 per cent from Rs 3,759 crore in the previous quarter (Q4 FY21).
Read More
Lupin Q4 PAT up 18 pc at Rs 460 crore on lower input costs
Updated : 4 years, 10 months ago IST
Mumbai (Maharashtra) [India], May 13 (ANI): Pharma major Lupin Ltd on Thursday reported 18 per cent jump in its consolidated profit after tax to Rs 460 crore.
Read More
Lupin Q1 net profit falls 60 pc to Rs 107 cr
Updated : 5 years, 7 months ago IST
Mumbai (Maharashtra) [India], Aug 7 (ANI): Pharma major Lupin Ltd has reported 60 per cent year-on-year decline in its net profit for the April to June quarter at Rs 107 crore.
Read More
Lupin launches Favipiravir in India for COVID treatment at Rs 49 per table
Updated : 5 years, 7 months ago IST
Mumbai (Maharashtra) [India], Aug 5 (ANI): Pharma major Lupin Ltd on Wednesday announced the launch of Favipiravir in India under the brand name Covihalt for treatment of mild to moderate COVID-19.
Read More
Lupin's Q4 net profit rises 35 pc to Rs 390 crore
Updated : 5 years, 9 months ago IST
Mumbai (Maharashtra) [India], May 29 (ANI): Pharma major Lupin Ltd has reported 34.5 per cent rise in its consolidated net profit to Rs 389.6 crore for the January to March quarter (Q4 FY20) as compared to Rs 289.5 crore in the corresponding period of previous fiscal.
Read More
Lupin contributes Rs 21 crore towards COVID-19 relief efforts
Updated : 5 years, 11 months ago IST
Mumbai (Maharashtra) [India], April 11 (ANI): Pharma major Lupin Ltd on Saturday announced a contribution of Rs 21 crore for relief efforts directed towards mitigating the COVID-19 crisis.
Read More
Lupin's Aurangabad facility gets EIR from US FDA
Updated : 5 years, 11 months ago IST
Mumbai (Maharashtra) [India], Apr 3 (ANI): Pharma major Lupin Ltd said on Friday it has got an establishment inspection report (EIR) from the US Food and Drug Administration for its Aurangabad facility.
Read More
Lupin's Pithampur facilities complete successful MHRA inspection
Updated : 6 years, 1 month ago IST
Mumbai (Maharashtra) [India], Jan 27 (ANI): Pharma major Lupin Ltd on Monday announced the successful completion of inspection carried out by the UK Medicines and Healthcare products Regulatory Agency (MHRA) at its three manufacturing units in Pithampur town of Madhya Pradesh.
Read More
Lupin's Ankleshwar cacility wins Frost & Sullivan's India manufacturing ex
Updated : 6 years, 2 months ago IST
Mumbai (Maharashtra) [India], Dec 24 (ANI): Pharma major Lupin Ltd said on Tuesday that its Ankleshwar facility has been awarded 'Future Ready Factory of the Year' by Frost & Sullivan's India Manufacturing Excellence Awards (IMEA) 2019.
Read More
Lupin announces completion of Kyowa divestiture to Unison
Updated : 6 years, 2 months ago IST
Mumbai (Maharashtra) [India], Dec 17 (ANI): Pharma major Lupin Ltd said on Tuesday that its subsidiary Nanomi BV has completed the divestiture of the entire 99.82 per cent stake in Kyowa Pharmaceutical Industry Co Ltd to Unison Capital Partners IV.
Read More
Japan's PMDA issues GMP certificate to Lupin's unit at Mandideep facility
Updated : 6 years, 5 months ago IST
Mumbai (Maharashtra) [India], Oct 9 (ANI): Pharma major Lupin Ltd on Wednesday announced the receipt of good manufacturing practice (GMP) certificate from the Pharmaceutical and Medical Devices Agency (PMDA) of Japan for its active pharmaceutical ingredient facility at Mandideep in Madhya Pr
Read More
Lupin closes offloading of Japanese subsidiary Kyowa Criticare to Neopharm
Updated : 6 years, 5 months ago IST
Mumbai (Maharashtra) [India], Sep 30 (ANI): Pharma major Lupin Ltd said on Monday it has closed a definitive agreement for the sale of its Japanese injectables business and related assets to Neo Ala Co Ltd, a wholly-owned subsidiary of Neopharma Group which is the UAE's largest pharmaceutica
Read More